|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Seminars in DialysisVolume 20 Issue 5, Pages 383 - 386 Published Online: 29 Jun 2007 © 2009 Wiley Periodicals, Inc. Published in association with the American Society of Diagnostic and Interventional Nephrology
Abstract | References | Full Text: HTML, PDF (Size: 457K) | Related Articles | Citation Tracking  Inadequate Treatment of Congestive Heart Failure in Dialysis Patients Copyright Journal compilation 2007 Blackwell Publishing Abstract
Congestive heart failure (CHF) is highly prevalent in patients on renal replacement therapy and is a leading cause of death in such patients. Several studies suggest that therapeutic agents for the treatment of CHF, particularly angiotensin converting enzyme inhibitors and beta-blockers, are underused in end-stage renal disease patients with CHF. Although limited data are available, growing evidence suggests that therapeutic agents for CHF improve survival and are safe to use, assuming close monitoring of adverse events. The reluctance of physicians in prescribing these therapeutic agents and the reasons underlying the inconsistent use of these agents in the dialysis population need to be addressed. | 
|
